{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:13:40Z","timestamp":1788614020665,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.seminoncol.2026.152517","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:58:15Z","timestamp":1781312295000},"page":"152517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives"],"prefix":"10.1016","volume":"53","author":[{"given":"Dana H.","family":"Elkhalifa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-9578","authenticated-orcid":false,"given":"Frank G.A.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152517_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq284","article-title":"Anemia in cancer","volume":"21","author":"Dicato","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0002","series-title":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity","year":"2011"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.23628","article-title":"Diagnosis and treatment of cancer-related anemia","volume":"89","author":"Gilreath","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/nu13020482","article-title":"Cancer related anemia: an integrated multitarget approach and lifestyle interventions","volume":"13","author":"Natalucci","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01294","article-title":"Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach","volume":"9","author":"Madeddu","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152426","article-title":"Mapping the epidemiology of cancer-related anemia: a systematic scoping review of global prevalence and incidence","volume":"52","author":"Elkhalifa","year":"2025","journal-title":"Semin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0007","doi-asserted-by":"crossref","first-page":"628","DOI":"10.6004\/jnccn.2012.0064","article-title":"Cancer- and chemotherapy-induced anemia","volume":"10","author":"Rodgers","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0008","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0009","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0010","series-title":"StatPearls [Internet]","article-title":"Erythropoietin stimulating agents","author":"Schoener","year":"2025"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3345\/cep.2023.01732","article-title":"Absolute versus functional iron deficiency","volume":"68","author":"Jung","year":"2024","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0012","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0013","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.2019004017","article-title":"How I treat cancer-associated anemia","volume":"136","author":"Gilreath","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0014","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2011-S3-12","article-title":"Management of anemia in cancer patients: transfusions","volume":"16","author":"Schrijvers","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12094-021-02580-2","article-title":"SEOM clinical guidelines for anaemia treatment in cancer patients","volume":"23","author":"Escobar \u00c1lvarez","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0016","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12964-023-01145-w","article-title":"Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy","volume":"21","author":"Yuan","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0017","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0018","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1525-1438.2007.01032.x","article-title":"Effects of anemia correction with epoetin beta in patients receiving","author":"Strauss","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtho.2019.10.005","article-title":"A randomized, double-blind, placebo-controlled, phase III noninferiority study of the long-term safety and efficacy of darbepoetin alfa for chemotherapy-induced anemia in patients with advanced NSCL","volume":"15","author":"Gasc\u00f3n","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0022","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3816\/CBC.2005.n.050","article-title":"Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly","volume":"6","author":"Senecal","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0023","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1634\/theoncologist.2009-0279","article-title":"Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial","volume":"15","author":"Pronzato","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0024","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.9-6-696","article-title":"A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa","volume":"9","author":"Schwartzberg","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clon.2008.06.001","article-title":"Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy","volume":"20","author":"Krzakowski","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.4966","article-title":"Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia","volume":"27","author":"Winquist","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0027","first-page":"151","article-title":"The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer","volume":"4","author":"Hiradfar","year":"2014","journal-title":"Iran J Ped Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0028","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1200\/JCO.2009.22.3693","article-title":"Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0029","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0030","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","article-title":"Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies","volume":"107","author":"Straus","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hon.722","article-title":"Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy","volume":"21","author":"Littlewood","year":"2003","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0032","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/003655901750425864","article-title":"Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer\u2013a randomized study","volume":"35","author":"Johansson","year":"2001","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0034","first-page":"45","article-title":"Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and and considerations in special populations","volume":"16","author":"Vansteenkiste","year":"2002","journal-title":"Oncology (Williston Park)"},{"issue":"28","key":"10.1016\/j.seminoncol.2026.152517_bib0035","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","article-title":"Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials","volume":"23","author":"Hedenus","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0036","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jjco\/hyn151","article-title":"Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer","volume":"39","author":"Tsuboi","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0037","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jjco\/hyl097","article-title":"Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: a randomized, double-blind, dose-finding study","volume":"36","author":"Morishima","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0038","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","article-title":"Effect of once-weekly epoetin beta on survival in patients with metastatic breast receiving anthracycline- and\/or taxane-based chemotherapy: results of the breast cancer\u2014anemia and the value of erythropoietin (BRAVE) study","volume":"26","author":"Aapro","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0039","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1634\/theoncologist.12-6-727","article-title":"Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JTO.0b013e318031cd9a","article-title":"A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy","volume":"2","author":"Crawford","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0042","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"20","author":"Wright","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0043","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10245330701521572","article-title":"Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0044","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.12-10-1253","article-title":"A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ajh.24110","article-title":"A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia","volume":"90","author":"Steensma","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0046","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/annonc\/mdn750","article-title":"A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group","volume":"20","author":"Ray-Coquard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0047","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1634\/theoncologist.2007-0241","article-title":"Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study","volume":"13","author":"Gordon","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0048","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0049","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.bjc.6600465","article-title":"Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy","volume":"87","author":"Glaspy","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0050","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/cncr.11186","article-title":"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease","volume":"97","author":"Glaspy","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0051","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","article-title":"Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group","volume":"64","author":"Bamias","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0052","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0053","first-page":"168","article-title":"HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours","volume":"32","author":"Weigang-K\u00f6hler","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0054","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S2352-3026(22)00402-1","article-title":"Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial","volume":"10","author":"Talboom","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270640","article-title":"Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: a pilot randomised controlled trial","volume":"17","author":"Fung","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0056","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/anae.14659","article-title":"The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial","volume":"74","author":"Keeler","year":"2019","journal-title":"Anaesthesia"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0057","first-page":"14","article-title":"Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents","author":"Noronha","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0058","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S138474","article-title":"Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer","volume":"8","author":"Vadhan-Raj","year":"2017","journal-title":"J Blood Med"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0059","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/bjs.10328","article-title":"Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer","volume":"104","author":"Keeler","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/phar.1729","article-title":"A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial","volume":"36","author":"Birgeg\u00e5rd","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0061","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-014-0302-3","article-title":"Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy","volume":"31","author":"Hedenus","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2012.06.003","article-title":"Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate","volume":"66","author":"Ferrari","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0063","first-page":"7645","article-title":"Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA","volume":"30","author":"Zuccarini","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0064","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1548-5315(12)70022-0","article-title":"IV iron sucrose for cancer and\/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents","volume":"8","author":"Anthony","year":"2011","journal-title":"Community Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0065","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2010-0020","article-title":"Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study","volume":"15","author":"Macci\u00f2","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0066","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajh.21779","article-title":"Darbepoetin alfa 300 or 500 \u00b5g once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"85","author":"Auerbach","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0067","first-page":"619","article-title":"Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study","volume":"17","author":"Heras","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0068","first-page":"3495","article-title":"Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment","volume":"25","author":"Mystakidou","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0069","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0070","first-page":"9","article-title":"Recombinant human erythropoietin in children with solid tumors and chemotherapy-induced anemia","volume":"10","author":"Ataollah Hiradfar","year":"2018","journal-title":"Iran J Blood Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-007-0561-1","article-title":"A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer","volume":"62","author":"Park","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0072","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:22:2:161","article-title":"Anemia in cervical cancer patients: implications for iron supplementation therapy","volume":"22","author":"Candelaria","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0073","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0074","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00277-015-2489-6","volume":"94","author":"Becker","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12905-022-01824-9","article-title":"Safety and efficacy of Ninjin\u2019yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial","volume":"22","author":"Yagi","year":"2022","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0076","first-page":"83","article-title":"Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients","volume":"24","author":"Lissoni","year":"2003","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0077","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0078","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428190701471981","article-title":"Decitabine and its role in the treatment of hematopoietic malignancies","volume":"48","author":"Plimack","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0079","author":"Roy"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0300891620921942","article-title":"Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines","volume":"106","author":"Sbrana","year":"2020","journal-title":"Tumori"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0081","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0082","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.21953","article-title":"2007 Standards, Options, and Recommendations: use of erythropoiesis- stimulating agents (ESA: Epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer","volume":"53","author":"Marec-Berard","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0083","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3747\/co.2007.149","article-title":"Canadian supportive care recommendations for the management of anemia in patients with cancer","volume":"14","author":"Mikhael","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0084","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0043-1771445","article-title":"Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries","volume":"12","author":"Parikh","year":"2023","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0085","article-title":"Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)","volume":"1","author":"Sun","year":"2012","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0086","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0087","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"2012","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0088","first-page":"268","article-title":"Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis","volume":"26","author":"Li","year":"2014","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0089","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cas.12105","article-title":"Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: individual patient data from Japanese randomized, placebo-controlled trials","volume":"104","author":"Ohashi","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0090","first-page":"547","article-title":"Efficacy and safety of combined administration of erythropoietin and iron in comparison to iron therapy alone in orthopaedic surgery: systematic review and metanalysis","volume":"35","author":"Kaur","year":"2021","journal-title":"Acta Ortop Mex"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0091","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ijc.34142","article-title":"The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents","volume":"151","author":"Tan","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11144156","article-title":"Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Buchrits","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0093","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/CCO.0000000000001024","article-title":"A meta-analysis on the risk of infection associated with intravenous iron therapy in cancer-associated anaemia: a double-edged sword?","volume":"36","author":"Meyers","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0094","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/0284186X.2012.702921","article-title":"Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials","volume":"52","author":"Gafter-Gvili","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0095","article-title":"The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents","volume":"2","author":"Mhaskar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0096","article-title":"Blood transfusions for anaemia in patients with advanced cancer","volume":"2012","author":"Preston","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0097","article-title":"Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support","volume":"5","author":"Radford","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seminoncol.2026.152517_bib0098","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/anae.13773","article-title":"International consensus statement on the peri-operative management of anaemia and iron deficiency","volume":"72","author":"Mu\u00f1oz","year":"2017","journal-title":"Anaesthesia"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:47:20Z","timestamp":1788612440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0093775426000643"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152517","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152517"}}